Enhabit, Inc. (EHAB) P/E Ratio History
Historical price-to-earnings valuation from 2022 to 2023
Loading P/E history...
Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of March 1, 2026, Enhabit, Inc. (EHAB) trades at a price-to-earnings ratio of -4.4x, with a stock price of $13.61 and trailing twelve-month earnings per share of $-0.23.
The current P/E is 137% below its 5-year average of 11.9x. Over the past five years, EHAB's P/E has ranged from a low of 8.3x to a high of 17.7x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.7x, EHAB trades at a 118% discount to its sector peers. The sector includes 224 companies with P/E ratios ranging from 0.0x to 184.4x.
Relative to the broader market, EHAB trades at a notable discount to the S&P 500 median P/E of 26.2x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our EHAB DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
Peer Comparison
P/E metrics vs. Home-based care services peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
CHEChemed Corporation | $6B | 22.3 | - | -7% |
OPCHOption Care Health, Inc. | $5B | 25.4 | - | +4% |
ADUSAddus HomeCare Corporation | $2B | 19.9 | 0.99Best | +23% |
DCGODocGo Inc. | $73M | 4.0Lowest | - | +177%Best |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
Historical P/E Data
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2023 Q1 | Fri Mar 31 2023 00:00:00 GM | $13.91 | $0.78 | 17.7x | +49% |
| FY2022 Q4 | Sat Dec 31 2022 00:00:00 GM | $13.16 | $1.25 | 10.5x | -11% |
| FY2022 Q3 | Fri Sep 30 2022 00:00:00 GM | $14.04 | $1.70 | 8.3x | -30% |
| FY2022 Q2 | $22.97 | $2.09 | 11.0x | -7% |
Average P/E for displayed period: 11.9x
See EHAB's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs EHAB Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare EHAB vs AGIO
See how EHAB stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is EHAB stock overvalued or undervalued?
EHAB trades at -4.4x P/E, below its 5-year average of 11.9x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does EHAB's valuation compare to peers?
Enhabit, Inc. P/E of -4.4x compares to sector median of 23.7x. The discount suggests lower growth expectations or higher risk.
What is EHAB's PEG ratio?
EHAB PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2022-2023.